https://www.selleckchem.com/pr....oducts/Mubritinib-TA
sed delivery of ART for stable PLHIV in high-burden resource-limited settings. This trial will inform policy regarding best practices and what is needed to strengthen scale-up of differentiated models of ART delivery in resource-limited settings. ClinicalTrials.gov NCT03025165 . Registered on 19 January 2017. ClinicalTrials.gov NCT03025165 . Registered on 19 January 2017. Immunosuppression including high-dose calcineurin inhibitors (CNI) is essential after lung transplantation. Dosing is usually guided by therapeutic drug mon
Like
Comment
Share
